<DOC>
	<DOCNO>NCT01833572</DOCNO>
	<brief_summary>This open-label , single-arm , phase II interventional clinical trial . The investigator hypothesize application EGFR-TKI , like gefitinib efficient safe neo-adjuvant setting . 42 resectable stage II-IIIa NSCLC patient EGFR activate ( 19/21 ) mutation eligible enrol . EGFR mutation prospectively test participant ' biopsy sample confirm surgical resect sample . Eligible patient give gefitinib 250mg 42days follow surgical resection tumor . Efficacy preoperative gefitinib base radiographic ( CT response/ORR ) , pathologic ( pathologic response ) , surgical ( complete resection ) evaluation , safety base adverse effect evaluation .</brief_summary>
	<brief_title>Preoperative Gefitinib EGFR Mutant II-IIIa NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Provision inform consent 2 . Pathologically confirm nonsmall cell lung cancer EGFR exon 19 deletion exon 21 L858 mutation . 3 . Clinically pathologically confirm stage IIIIIA 4 . Tolerable complete resection lung cancer 5 . Male female age 18 year 6 . Able comply require protocol followup procedure , able receive oral medication 7 . ECOG performance status 01 . 8 . Life expectancy ≥12 week . 9 . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥2.0 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . 10 . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) . 11 . Adequate renal function : Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) , creatinine clearance≥ 60 ml/min . 12 . Measurable disease accord preset criterion . 1 . Known severe hypersensitivity gefitinib excipients product 2 . Any serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability complete study 3 . Interstitial lung disease ( ILD ) pulmonary fibrosis ; impaired pulmonary function ( e.g . FEV1 &lt; 40 % predict value , artery blood gas PaO2 &lt; 60mmHg ) 4 . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . 5 . Patients prior exposure chemotherapy , irradiation systemic anticancer therapy ( e.g . monoclonal antibody therapy ) lung cancer . 6 . Previous current malignancy histology within last 5 year exception following : malignancy cure surgery alone continuous diseasefree survival 5 year ; cure basal cell carcinoma skin cure situ carcinoma uterine cervix . 7 . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within six month , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . 8 . Eye inflammation eye infection fully treat predispose factor . 9 . Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication . 10 . Patient serious active infection 11 . Patients harbour exon 20 T790M mutation . 12 . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>gefitinib</keyword>
	<keyword>neo-adjuvant therapy</keyword>
</DOC>